Systemic and localized scleroderma

Clinics in Dermatology

Volumn 24, Issue 5, 2006, Pages 374-392

  Chung, Lorinda ^a   Lin, Jan ^b   Furst, Daniel E ^b   Fiorentino, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOSENTAN; CALCIPOTRIOL; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; FLUOROURACIL; GAMMA INTERFERON; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PENICILLAMINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTON PUMP INHIBITOR; RELAXIN; SILDENAFIL; TACROLIMUS; TEGASEROD; UNINDEXED DRUG;

ANTIBODY DETECTION; ARTICLE; BACTERIAL OVERGROWTH; CALCINOSIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CROW FUKASE SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENDOSCOPIC THERAPY; EOSINOPHILIC FASCIITIS; ESOPHAGUS STRICTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; HEAD AND NECK DISEASE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFLUENZA; KIDNEY DISEASE; LOCALIZED SCLERODERMA; LUNG ALVEOLITIS; MORPHEA; MUSCULOSKELETAL DISEASE; MYOCARDITIS; NEPHROGENIC FIBROSING DERMOPATHY; NEUROLOGICAL COMPLICATION; ONSET AGE; PARAPROTEINEMIA; PATHOGENESIS; PERICARDITIS; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PUVA; RAYNAUD PHENOMENON; RHEUMATIC DISEASE; SCLEREDEMA; SCLEROMYXEDEMA; SEX RATIO; SKIN ULCER; STEM CELL TRANSPLANTATION; STREPTOCOCCUS PNEUMONIA; SYSTEMIC SCLEROSIS; UROGENITAL TRACT DISEASE; VACCINATION; XEROSTOMIA;

ANTIPRURITICS; DIAGNOSIS, DIFFERENTIAL; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHYSICAL THERAPY MODALITIES; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES;

EID: 33748308825     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.07.004     Document Type: Article

References (180)

1. Peterson L., et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 24 (1997) 73-80
2. Provost T., Greenberg A., and Falanga V. Localized cutaneous sclerosis. In: Sontheimer R., and Provost T. (Eds). Cutaneous manifestations of rheumatic diseases (2004), Lippincott Williams & Wilkins, Philadelphia 125-134
3. Prescott R., Freemont A.J., Jones C.J., Hoyland J., and Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166 (1992) 255-263
4. Hasegawa M., Sato S., and Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 117 (1999) 159-165
5. Kowalewski C., et al. Alterations of basement membrane zone and cutaneous microvasculature in morphea and extragenital lichen sclerosus. Am J Dermatopathol 27 (2005) 489-496
6. Kahaleh M. The role of vascular endothelium in the pathogenesis of connective tissue disease: endothelial injury, activation, participation and response. Clin Exp Rheumatol 8 (1990) 595-601
7. Zulian F. Systemic manifestations in localized scleroderma. Curr Rheumatol Rep 6 (2004) 417-424
8. Hasegawa M., et al. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 207 (2003) 141-147
9. Jinnin M., et al. Serum levels of manganese superoxide dismutase in patients with localized scleroderma. Exp Dermatol 13 (2004) 357-360
10. Liu B., and Connolly M. The pathogenesis of cutaneous fibrosis. Semin Cutan Med Surg 17 (1998) 3-11
11. Kubo M., Ihn H., Yamane K., and Tamaki K. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 44 (2001) 731-734
12. Tuffanelli D. Localized scleroderma. Semin Cutan Med Surg 17 (1998) 27-33
13. Weide B., Walz T., and Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol 142 (2000) 636-644
14. O'Leary P., and Nomland R. Clinical study of 103 cases of scleroderma. Am J Med Sci 180 (1930) 95-112
15. Peterson L., Nelson A., and Su W. Classification of morphea (localized scleroderma). Mayo Clin Proc 70 (1995) 1068-1076
16. Cannick L., et al. Nodular scleroderma: case report and literature review. J Rheumatol 30 (2003) 2500-2502
17. Rencic A., Brinster N., and Nousari C. Keloid morphea and nodular scleroderma: two distinct clinical variants of scleroderma?. J Cutan Med Surg 7 (1999) 20-24
18. Jablonska S., and Blaszczyk M. Is superficial morphea synonymous with atrophoderma Pasini-Pierini?. J Am Acad Dermatol 50 (2004) 979-980 [author reply 980]
19. McNiff J., et al. Morphea limited to the superficial reticular dermis: an underrecognized histologic phenomenon. J Am Acad Dermatol 21 (1999) 315-319
20. Rencic A., et al. Bullous lesions in scleroderma. Int J Dermatol 41 (2002) 335-339
21. Zulian F., et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52 (2005) 2873-2881
22. Soma Y., and Fujimoto M. Frontoparietal scleroderma (en coup de sabre) following Blaschko's lines. J Am Acad Dermatol 38 2 Pt 2 (1998) 366-368
23. Orozco-Covarrubias L., et al. Scleroderma 'en coup de sabre' and progressive facial hemiatrophy. Is it possible to differentiate them?. J Eur Acad Dermatol Venereol 16 (2002) 361-366
24. Menni S., Marzano A., and Passoni E. Neurologic abnormalities in two patients with facial hemiatrophy and sclerosis coexisting with morphea. Pediatr Dermatol 14 (1997) 113-116
25. Appenzeller S., et al. Neuroimaging findings in scleroderma en coup de sabre. Neurology 62 (2004) 1585-1589
26. Su W., and Person J. Morphea profunda. A new concept and a histopathologic study of 23 cases. Am J Dermatopathol 3 (1981) 251-260
27. Shulman L. Diffuse fasciitis with eosinophilia: a new syndrome?. Trans Assoc Am Physicians 88 (1975) 70-86
28. Doyle J.A., and Ginsburg W.W. Eosinophilic fasciitis. Med Clin North Am 73 (1989) 1157-1166
29. Khanna D., Verity A., and Grossman J. Eosinophilic fasciitis with multiple myeloma: a new haematological association. Ann Rheum Dis 61 (2002) 1111-1112
30. Aberer E., Klade H., and Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am J Dermatopathol 13 (1991) 334-341
31. Falanga V., and Medsger T. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol 17 (1987) 648-656
32. Falanga V., et al. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 104 (1986) 849-857
33. Takehara K., and Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology 44 (2005) 274-279
34. Mimura Y., et al. Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol 30 (2005) 405-408
35. Hayakawa I., et al. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum 50 (2004) 227-232
36. Arnett F., et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum 42 (1999) 2656-2659
37. Christianson H., et al. Localized scleroderma; a clinical study of two hundred thirty-five cases. A.M.A. Arch Dermatol 74 (1956) 629-639
38. Hulshof M., et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 43 (2000) 1017-1023
39. Hunzelmann N., et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 36 3 Pt 1 (1997) 433-435
40. Mancuso G., and Berdondini R. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 152 (2005) 180-182
41. Cunningham B., et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 39 2 Pt 1 (1998) 211-215
42. Dytoc M., et al. First case series on the use of imiquimod for morphoea. Br J Dermatol 153 (2005) 815-820
43. Kerscher M., et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 38 (1998) 21-26
44. de Rie M., et al. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 207 (2003) 298-301
45. Camacho N., et al. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 45 (2001) 697-699
46. Kreuter A., et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 18 (2001) 241-245
47. El-Mofty M., et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. PhotodermatolPhotoimmunol Photomed 20 (2004) 148-156
48. Stege H., et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 36 6 Pt 1 (1997) 938-944
49. El-Mofty M., et al. Low-dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed 16 (2000) 43-49
50. Kerscher M., et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol 132 (1996) 1280-1282
51. Joly P., et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 130 (1994) 663-664
52. Falanga V., and Medsger T. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 126 (1990) 609-612
53. Seyger M., et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 39 2 Pt 1 (1998) 220-225
54. Uziel Y., et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 136 (2000) 91-95
55. Kreuter A., et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 141 (2005) 847-852
56. Elst E., Van Suijlekom-Smit L., and Oranje A. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 16 (1999) 53-58
57. Caca-Biljanovska N., et al. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 455 (1999) 299-304
58. Fisher G., and Kang S. Phototherapy for scleroderma: biologic rationale, results, and promise. Curr Opin Rheumatol 14 (2002) 723-726
59. Cribier B., et al. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology 191 (1995) 25-31
60. Romano C., et al. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol 17 (2003) 10-13
61. Clements P.J., and Furst D. Systemic sclerosis. 2nd ed. (2004), Lippincott Williams and Wilkins, Philadelphia
62. Furst D.E., et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 32 (1989) 584-593
63. Clements P., et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42 (1999) 1194-1203
64. Steen V.D., et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76 (1984) 779-786
65. Arnett F.C., et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 39 (1996) 1362-1370
66. Arnett F.C., et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44 (2001) 1359-1362
67. Mayes M., and Reveille J.D. Epidemiology, demographics and genetics. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 1-15
68. Reveille J.D., et al. HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjogren's syndrome and progressive systemic sclerosis: a question of disease relevance. Tissue Antigens 40 (1992) 45-48
69. Reveille J.D., et al. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest 89 (1992) 1208-1213
70. Nelson J.L. Microchimerism and HLA relationships of pregnancy: implications for autoimmune diseases. Curr Rheumatol Rep 3 (2001) 222-229
71. Artlett C.M. Microchimerism and scleroderma: an update. Curr Rheumatol Rep 5 (2003) 154-159
72. Christner P.J., et al. Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride. Arthritis Rheum 43 (2000) 2598-2605
73. Jimenez S.A., and Artlett C.M. Microchimerism and systemic sclerosis. Curr Opin Rheumatol 17 (2005) 86-90
74. Hamamdzic D., et al. MCMV induces neointima in IFN-gammaR-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskelet Disord 2 (2001) 3
75. Ohtsuka T., and Yamazaki S. Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol 150 (2004) 1091-1095
76. Parks C.G., Conrad K., and Cooper G.S. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107 Suppl 5 (1999) 793-802
77. Haustein U.F., and Anderegg U. Silica induced scleroderma-clinical and experimental aspects. J Rheumatol 25 (1998) 1917-1926
78. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 14 (2002) 681-685
79. Ihn H., et al. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 44 (2001) 474-480
80. Kucich U., et al. Transforming growth factor-beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-delta, and p38. Am J Respir Cell Mol Biol 26 (2002) 183-188
81. Schachna L., and Wigley F.M. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 14 (2002) 686-693
82. LeRoy E.C. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22 (1996) 675-694
83. Abraham D.J., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151 (1997) 831-841
84. Hitraya E.G., et al. Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 41 (1998) 2048-2058
85. Zhang W., et al. Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2(I)-collagen (COL1A2) transcription. J Biol Chem 275 (2000) 39237-39245
86. Medsger T.A. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman W.J. (Ed). Arthritis and allied conditions: a textbook of rheumatology (2000), Lippincott Williams and Wilkins, Philadelphia 1590-1624
87. LeRoy E.C., and Medsger Jr. T.A. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 10 (1992) 485-488
88. Steen V.D., and Medsger Jr. T.A. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 40 (1997) 1146-1151
89. Clements P.J., et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 21 (1978) 62-71
90. Rose S., Young M.A., and Reynolds J.C. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 27 (1998) 563-594
91. Weinstein W.M., and Kadell B.M. The gastrointestinal tract in systemic sclerosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 293-308
92. Schuffler M.D., and Beegle R.G. Progressive systemic sclerosis of the gastrointestinal tract and hereditary hollow visceral myopathy: two distinguishable disorders of intestinal smooth muscle. Gastroenterology 77 4 Pt 1 (1979) 664-671
93. Steen V.D., et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113 (1990) 352-357
94. Steen V.D., and Medsger Jr. T.A. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 16 (1990) 1-10
95. Steen V. Renal involvement in systemic sclerosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 279-292
96. Traub Y.M., et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62 (1983) 335-352
97. Tuffanelli D.L., and Winkelmann R.K. Systemic scleroderma, a clinical study of 727 cases. Arch Dermatol 84 (1961) 359-371
98. Livi R., et al. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 61 (2002) 682-686
99. Medsger Jr. T.A., and Masi A.T. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 26 (1973) 647-660
100. Medsger Jr. T.A., et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75 (1971) 369-376
101. Hong P., et al. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. J Rheumatol 31 (2004) 508-513
102. Nowlin N.S., et al. Impotence in scleroderma. Ann Intern Med 104 (1986) 794-798
103. Nehra A., et al. Systemic sclerosis and impotence: a clinicopathological correlation. J Urol 153 (1995) 1140-1146
104. Steen V. Sexual dysfunction and pregnancy in systemic sclerosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 319-330
105. Bhadauria S., et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol 172 2 Pt 1 (1995) 580-587
106. Englert H., et al. Reproductive function prior to disease onset in women with scleroderma. J Rheumatol 19 (1992) 1575-1579
107. Steen V.D., et al. Pregnancy in women with systemic sclerosis. Arthritis Rheum 32 (1989) 151-157
108. Steen V.D., and Medsger Jr. T.A. Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum 42 (1999) 763-768
109. Black C.M., and Stevens W.M. Scleroderma. Rheum Dis Clin North Am 15 (1989) 193-212
110. Weiner S.R. Organ function: sexual function and pregnancy. In: Clements P., and Furst D. (Eds). Systemic sclerosis (1995), Williams & Wilkins, Baltimore 483-499
111. Averbuch-Heller L., Steiner I., and Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 49 (1992) 1292-1295
112. Herrick A. Nervous system involvement in systemic sclerosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 309-317
113. Farrell D.A., and Medsger Jr. T.A. Trigeminal neuropathy in progressive systemic sclerosis. Am J Med 73 (1982) 57-62
114. Klimiuk P.S., et al. Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 47 (1988) 542-545
115. Medsger T.A. Systemic sclerosis and Raynaud syndrome. In: Koopman W.J., Boulware D.W., and Heudebert G.R. (Eds). Clinical primer of rheumatology (2003), Lippincott Williams and Wilkins, Philadelphia 171-181
116. Kuwana M., et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37 (1994) 75-83
117. Hu P.Q., et al. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48 (2003) 1363-1373
118. Satoh M., et al. Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. J Immunol 153 (1994) 5838-5848
119. Sacks D.G., et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 23 (1996) 639-642
120. Reveille J.D., and Solomon D.H. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49 (2003) 399-412
121. Poormoghim H., et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 43 (2000) 444-451
122. Fudman E.J., Golbus J., and Ike R.W. Scleromyxedema with systemic involvement mimics rheumatic diseases. Arthritis Rheum 29 (1986) 913-917
123. Kantor G.R., et al. Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol 14 5 Pt 2 (1986) 879-888
124. Gabriel S.E., et al. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 67 (1988) 58-65
125. Miralles G.D., O'Fallon J.R., and Talley N.J. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 327 (1992) 1919-1923
126. Bardwick P.A., et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 59 (1980) 311-322
127. Soubrier M.J., Dubost J.J., and Sauvezie B.J. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med 97 (1994) 543-553
128. Jablonska S., and Blaszczyk M. Scleroderma-like disorders. Semin Cutan Med Surg 17 (1998) 65-76
129. Jablonska S., and Blaszczyk M. Differential diagnosis of systemic sclerosis-like disorders. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 99-120
130. Venencie P.Y., et al. Scleredema: a review of thirty-three cases. J Am Acad Dermatol 11 (1984) 128-134
131. Cowper S.E., and Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25 (2003) 358
132. McNeill A.M., and Barr R.J. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol 41 (2002) 364-367
133. Streams B.N., et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 48 (2003) 42-47
134. Swartz R.D., et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114 (2003) 563-572
135. Cowper S.E. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15 (2003) 785-790
136. Perazella M.A., Ishibe S., and Reilly R.F. Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial 16 (2003) 276-280
137. Jimenez S.A., et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50 (2004) 2660-2666
138. Lacour J.P., et al. Fibroblastic rheumatism: clinical, histological, immunohistological, ultrastructural and biochemical study of a case. Br J Dermatol 128 (1993) 194-202
139. Vignon-Pennamen M.D., et al. Fibroblastic rheumatism. J Am Acad Dermatol 14 (1986) 1086-1088
140. Pedersen J.K., Poulsen T., and Horslev-Petersen K. Fibroblastic rheumatism: a Scandinavian case report. Ann Rheum Dis 64 (2005) 156-157
141. Janin-Mercier A., et al. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man. Am J Pathol 115 (1984) 296-306
142. Wolff D., et al. Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease. Bone Marrow Transplant 29 (2002) 357-360
143. Moreno J.C., et al. Bullous scleroderma-like changes in chronic graft-versus-host disease. J Eur Acad Dermatol Venereol 17 (2003) 200-203
144. Furst D.E., et al. A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. A model for scleroderma?. Arthritis Rheum 22 (1979) 904-910
145. Siimes M.A., Johansson E., and Rapola J. Scleroderma-like graft-versus-host disease as late consequence of bone-marrow grafting. Lancet 2 (1977) 831-832
146. Wigley F., and Hummers L. Managment: holistic approach to systemic sclerosis. A Physician's approach. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 371-384
147. Rosenkranz S., et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 139 (2003) 871-873
148. Clements P., Medsger T.A., and Feghali C.A. Cutaneous involvement in systemic sclerosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis (2004), Lippincott Williams and Wilkins, Philadelphia 129-150
149. Tashkin D.P., Elashoff R., Clements P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006) 2655-2666
150. How can treatment of systemic sclerosis be improved? By setting up a national database of all cases and entering patients into trials. UK Scleroderma Study Group. BMJ 317 (1998) 294-295
151. Furst D., Pope J., and Clements P. Systemic sclerosis. In: Tugwell P., et al. (Ed). Evidence-based rheumatology (2004), BMJ Books, London, UK 443-483
152. van den Hoogen F.H., et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35 (1996) 364-372
153. Pope J.E., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 (2001) 1351-1358
154. Casas J.A., et al. 5-Fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. Ann Rheum Dis 49 (1990) 926-928
155. Lin A.T., Clements P.J., and Furst D.E. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am 29 (2003) 409-426
156. Binks M., et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 60 (2001) 577-584
157. McSweeney P.A., et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100 (2002) 1602-1610
158. Furst D.E. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 14 (2002) 220-224
159. Ziesche R., et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 (1999) 1264-1269
160. Polisson R.P., et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 23 (1996) 654-658
161. Black C.M., et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42 (1999) 299-305
162. Clements P.J., et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42 (1999) 1194-1203
163. Seibold J.R., et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 132 (2000) 871-879
164. Rubens C., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120 (2001) 1562-1569
165. Wax D., Garofano R., and Barst R.J. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 116 (1999) 914-920
166. Galie N., Manes A., and Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 22 (2001) 529-537
167. Simonneau G., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
168. Olschewski H., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160 (1999) 600-607
169. Olschewski H., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
170. Channick R.N., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
171. Rubin L.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
172. Abrams D., Schulze-Neick I., and Magee A.G. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84 (2000) E4
173. Prasad S., Wilkinson J., and Gatzoulis M.A. Sildenafil in primary pulmonary hypertension. N Engl J Med 343 (2000) 1342
174. Ghofrani H.A., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
175. Wilkens H., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
176. Ghofrani H.A., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
177. Weimann J., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92 (2000) 1702-1712
178. Gresser U., and Gleiter C.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res 7 (2002) 435-446
179. Sachse R, Rohde G. Tolerability and pharmacokinetics of multiple dose treatment with the new PDE5-inhibitor BAY 38-9456. in EULAR. 2000. Brussels.
180. Vobig M.A., et al. Retinal side-effects of sildenafil. Lancet 353 (1999) 375